Overview
Employees
1-10
Founded date
2013
Mentions in press and media 12
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 23, 2026 | Mstone Partners Healthcare Highlights Polaryx Therapeutics’ Latest Preclinical Data Shared at WORLDSymposium™ 2026 | Mstone Partners Healthcare HONG KONG, February 23, 2026 /EINPresswire.com/ -- Mstone Partners Healthcare (“Mstone”), a Hong Kong-based entrepreneurial biotech incubator in the form of a holding company, highlights the recent late-breaking p... |
| Mar 7, 2025 | Liberyx Therapeutics Announces the Appointment of Dr. Eddy Zhu as Chief CMC Officer | HONG KONG SAR, HONG KONG, March 7, 2025 /EINPresswire.com/ -- Liberyx Therapeutics, a clinical-stage biopharmaceutical company developing safe, effective, and patient-friendly drugs to treat rare, pediatric neurometabolic diseases, announce... |
| Aug 5, 2024 | Forest Hills Lab Enters Exclusive Worldwide Patent License Agreement to Incorporate FHL-101 for the Treatment of TBI | PARAMUS, NEW JERSEY, UNITED STATES, August 5, 2024 /EINPresswire.com/ -- Forest Hills Lab (“FHL”), an innovative global life sciences company focused on regenerative medicine and medical aesthetics, announced it has entered into an agreemen... |
| May 2, 2024 | Mstone Portfolio Company, Epygenix Therapeutics, Announces Agreement to be Acquired For Total Deal Value of $680M | HONG KONG SAR, May 2, 2024 /EINPresswire.com/ -- Mstone Partners (“Mstone”), an entrepreneurial biotech incubator in the form of a holding company, today announces that Epygenix Therapeutics, Inc. (“Epygenix”), an Mstone portfolio company, ... |
| Jan 31, 2024 | Forest Hills Lab Announces Results from Phase 1 Trial of FHL-101 Glyceryl Tribenzoate for Neurological Conditions | HONG KONG, SAR, January 31, 2024 /EINPresswire.com/ -- Forest Hills Lab (“FHL”), an innovative global life sciences company focused on regenerative medicine and medical aesthetics, announces successful completion of Phase 1 clinical trial f... |
| Nov 28, 2022 | Epygenix Therapeutics to Present at the American Epilepsy Society 2022 Annual Meeting in Nashville | PARAMUS, NJ, UNITED STATES, November 28, 2022 /EINPresswire.com/ -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing therapies for rare and intractable forms of genetic epilepsy, will a... |
| Oct 10, 2022 | Epygenix Therapeutics to Host Investor Meetings at the 2nd Annual Needham Biotech Private Company Virtual 1x1 Forum | PARAMUS, N.J., UNITED STATES, October 10, 2022 /EINPresswire.com/ -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing therapies for rare and intractable forms of genetic epilepsy, annou... |
| Sep 17, 2022 | Epygenix Therapeutics to Present at UBS Biotechnology Virtual Private Company Symposium | PARAMUS, NJ, UNITED STATES, September 17, 2022 /EINPresswire.com/ -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on genetically screening, discovering and developing safe, effective and patient-friendly drugs f... |
| May 10, 2022 | Forest Hills Lab Announces Additions to Cos-Med Division’s Leadership Team | Ella Fong joining as Chief Commercial Officer, Ik-Hwan Cho as CEO of NewMedic subsidiary HONG KONG, May 10, 2022 /EINPresswire.com/ -- Forest Hills Lab (FHL) is an innovative regenerative medicine company seeking to improve the quality of l... |
Show more
Reviews 0
FAQ about Mstone Partners
When was Mstone Partners founded?
Mstone Partners was founded in 2013.
What has the press written about Mstone Partners?
Parsers VC has collected 12 articles mentioning Mstone Partners, among them “Mstone Partners Healthcare Highlights Polaryx Therapeutics’ Latest Preclinical Data Shared at WORLDSymposium™ 2026” (Feb 23, 2026) and “Liberyx Therapeutics Announces the Appointment of Dr. Eddy Zhu as Chief CMC Officer” (Mar 7, 2025).
Is Mstone Partners still active?
Yes, Mstone Partners is active; its latest activity on Parsers VC dates from Feb 24, 2026.